81
37
Growth Score
-8 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
842595
Cyanvac develops vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector.
- Biao He: Founder and CEO
- Gary Titus: CFOPast Role: SciClone Pharmaceuticals, Consultant - Special Projects
About the Company
Cyanvac develops vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. It is currently focused on developing robust, intranasal vaccines that are easy to administer, easy to transport, and easy to manufacture.
Two of Cyanvac’s vaccine candidates are scheduled to enter clinical testing beginning in 2021,
including an intrasal vaccine to serve as a booster for protecting against SARS-CoV-2 infection. The candidate was selected for the trial by an academic consortium that has run government-funded trials for other COVID-19 vaccines, and the clinical evaluation will be conducted at no cost to Cyanvac.
Cyanvac also has vaccine candidates for the respiratory syncytial virus (RSV), norovirus, and Lyme Disease.
